Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial
N
Shared by NobleBlocks on Mar 1, 2020 • 12:00 AM UTC
Authors:
Robert H Jones
,
Angela Casbard
,
Margherita Carucci
Research Assistant
AI chat, annotations, notes & similar papers
Finding related papers...
Discussions
(0)
No comments yet
Be the first to share your thoughts!
Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial | NobleBlocks
